IntelGenx Corp. announced that it has received the first purchase order for RIZAFILM from its commercial partner in the United States, Gensco Pharma . The PO triggers an upfront order deposit payment.

A pre-specified milestone payment to IntelGenx from Gensco is also payable upon transfer of NDA. Both payments will be reflected in the Company?s third quarter of 2023 financial results. IntelGenx expects to ship the ordered RIZAFILM product to Gensco in the first quarter of 2024 for immediate launch.

RIZAFILM (U.S. market name for RIZAPORT) is a proprietary oral thin film formulation of rizatriptan benzoate. RizaFilm oral soluble film does not require a drink for swallowing and has ease of use which facilitates rapid administration and relief from migraine symptoms. RizaFilm?s active ingredient has been clinically proven to be effective for migraine associated nausea, photophobia and phonophobia.